Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1799 - Global Phase 3 Study of Tislelizumab Versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC): A Trial-in-Progress

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Shukui Qin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

S. Qin1, R.S. Finn2, M. Kudo3, T. Meyer4, A. Vogel5, M.P. Ducreux6, T.M. Macarulla7, G. Tomasello8, F. Boisserie9, J. Hou10, C. Li11, J. Song12, A.X. Zhu13

Author affiliations

  • 1 Medical Oncology, People’s Liberation Army (PLA) 81 Hospital, 210002 - Nanjing/CN
  • 2 School Of Medicine, University of California Los Angeles, 90095 - Los Angeles/US
  • 3 Department Of Gastroenterology And Hepatology, Kindai University School of Medicine, Osaka/JP
  • 4 Medical Oncology, University College London Cancer Institute, London/GB
  • 5 Medical Oncology, Medizinische Hochschule Hannover, Hannover/DE
  • 6 Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 7 Vall D'hebron Institute Of Oncology (vhio), Vall d'Hebron University Hospital (HUVH), Barcelona/ES
  • 8 Medical Oncology, Azienda Istituti Ospitalieri di Cremona, 26100 - Cremona/IT
  • 9 Clinical Science, BeiGene USA, Inc., Fort Lee/US
  • 10 Immuno-oncology, BeiGene USA, Inc., Emeryville/US
  • 11 Medical Oncology, BeiGene (Beijing) Co., Ltd., Beijing/CN
  • 12 Biometry, BeiGene USA, Inc., Fort Lee/US
  • 13 Harvard Medical School, Massachusetts General Hospital Cancer Center, 02114 - Boston/US
More

Resources

Abstract 1799

Background

Unresectable HCC accounts for 70% of diagnosed HCC. Tislelizumab is a humanized IgG4 monoclonal antibody with high affinity and specificity for programmed cell death receptor-1 (PD-1). Tislelizumab was specifically engineered to minimize FcϒR binding on macrophages that, based on preclinical evidence, is believed to minimize potentially negative interactions with other immune cells. A phase 1A/1B study (NCT02407990) demonstrated that single-agent tislelizumab was generally well tolerated and showed preliminary evidence of antitumor activity in patients with advanced solid tumors, including HCC. A recommended phase 3 dose of 200 mg administered intravenously (IV) every 3 weeks (Q3W) has been established for tislelizumab.

Trial design

This global, phase 3, randomized, multicenter study (NCT03412773) was designed to evaluate the efficacy and safety of tislelizumab compared with sorafenib as a potential first-line treatment of unresectable HCC. Adult patients, aged ≥18 years, with unresectable, histologically confirmed HCC, an ECOG score ≤1, Child-Pugh A classification, BCLC Stage C disease or BCLC Stage B disease that has relapsed after loco-regional therapy, and who have not received prior systemic therapy, are being enrolled. Approximately 640 patients from 100 international centers are planned to be randomized (1:1) to receive tislelizumab 200 mg IV Q3W or sorafenib 400 mg orally BID. The primary outcome of this study is overall survival (OS) of patients treated with tislelizumab compared with OS of patients treated with sorafenib; secondary outcomes include objective response rate, progression-free survival, duration of response, time to progression, and quality-of-life outcomes. Safety/tolerability assessments include monitoring adverse events (AEs), including immune-related AEs, as well as physical examinations, vital signs, and electrocardiograms. Exploratory endpoints include assessment of potential biomarkers, characterization of the tislelizumab pharmacokinetic profile in patients with HCC, and assessment of host immunogenicity to tislelizumab. As of 11 April 2018, 11 patients have been enrolled.

Clinical trial identification

NCT03412773.

Legal entity responsible for the study

Beigene, Ltd.

Funding

BeiGene, Ltd.

Editorial Acknowledgement

Medical writing and editorial assistance was provided by Regina Switzer, PhD (SuccinctChoice Medical Communications, Chicago, IL).

Disclosure

R.S. Finn: Consulting, Advisory role, Research funding: Pfizer, Bayer, Novartis, BMS. M. Kudo: Honrorara, Advisory role, Research funding: Chugai, Otuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Esiai, Bayer, Ajinomoto, Kowa, BMS, Abbvie. T. Meyer: Advisory role, Research funding: BMS, Merck, Beigene, Eisai, Bayer, BTG, Ipsen. A. Vogel: Advisory role, Research funding, Travel/accommodation/expenses, Honoraria: Novartis, MSD, BMS, Delcath Systems, Sanofi, Bayer, Ipsen, Roche. M.P. Ducreux: Ad boards, Symposiums, Research funding: Roche, Merck Serono, Amgen, Novartis, Sanofi, Bayer, Sirtex, Lilly, Servier, Ipsen, Pfizer. F. Boisserie, J. Hou, C. Li: C, J. Song: Employee: BeiGene. A.X. Zhu: Advisory role, Research funding: Eisai, BMS, Novartis, Merck, Sanofi, AstraZeneca, Exelixis, Bayer, Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.